RxDoctor Payments Data

Morgan Turner

Psychiatric/Mental Health · Chattanooga, TNNPI 1609295906

Payments from drug & device makers

$3,987in general payments, 2019–2025

Across 189 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$844
  • AbbVie$369
  • Corium, LLC$350
  • Otsuka America Pharmaceutical, Inc.$331
  • Alkermes, Inc.$281
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$252
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$3,987100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,987 in reported general payments places this provider in the 85th percentile of 1,167 psychiatric/mental health providers in Tennessee.

See all psychiatric/mental health providers in Tennessee

Medicare billing

Part B allowed, 2024
$20,066
Medicare patients
62
Services billed
246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aripiprazole51$2,626
Eszopiclone26$2,472
Lamotrigine147$2,193
Bupropion XlBupropion Hcl37$1,915
Quetiapine Fumarate83$1,783
Clonazepam222$1,447
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine49$1,319
Hydroxyzine Hcl28$898
Desvenlafaxine Succinate ErDesvenlafaxine Succinate15$872
Lurasidone Hcl23$797
Mirtazapine29$727
Quetiapine Fumarate ErQuetiapine Fumarate17$699
Escitalopram Oxalate47$621
Trazodone Hcl67$610
Zolpidem Tartrate ErZolpidem Tartrate21$509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$170$37630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,167 psychiatric/mental health providers in Tennessee.

Other psychiatric/mental health in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →